Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Galaxy Biosolutions AB
AB
In liquidation
Org 5594516535
Göteborg
Research and experimental development on natural sciences and engineering
· NACE 7210
Est. 2023
0 employees
Watchlist
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Galaxy Biosolutions AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2024
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2024
Income statement
SEK thousands
Item
2024
Revenue
0
Staff expenses
−645
EBITDA
−435
Depreciation & amort.
—
EBIT
−435
Net financials
4
Profit before tax
—
Tax
—
Net profit
−431
Balance sheet
SEK thousands
Item
2024
Total assets
584
Equity
19
Long-term debt
59
Short-term debt
507
Total debt
566
Financial ratios
5-year trend
EBITDA margin
-43538700.0%
This company
15.8%
Market median
-275561492% vs market
2024
2024
Equity ratio
3.2%
This company
38.2%
Market median
-92% vs market
2024
2024
Return on equity
-2329.9%
This company
18.4%
Market median
-12763% vs market
2024
2024
Net profit margin
-43148100.0%
This company
8.1%
Market median
-532692693% vs market
2024
2024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2024
2024
Debt / equity
30.56×
This company
0.62×
Market median
-4829% vs market
2024
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-10-10 – 2024-12-31
View
PDF
More on Galaxy Biosolutions AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
